Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Sofosbuvir/ledipasvir cures nearly all genotype 1 HCV for people with HIV co-infection

All but one participant treated for hepatitis C virus (HCV) with a co-formulation of sofosbuvir and ledipasvir (Harvoni) achieved sustained virological response at 12 weeks post-treatment, in a

Published
10 November 2014
By
Liz Highleyman
Sustained virological response to hepatitis C treatment reduces mortality, liver cancer and liver transplants

People who achieve sustained virological response (SVR) when treated with interferon-based therapy for hepatitis C have a lower risk of death, are less likely to develop liver

Published
10 November 2014
By
Liz Highleyman
Olysio (simeprevir) approved for use in combination with sofosbuvir

Janssen Therapeutics, Division of Janssen Products, LP (Janssen) announced the U.S. Food and Drug Administration (FDA) has approved OLYSIO® (simeprevir), a hepatitis C virus (HCV) NS3/4A protease inhibitor, in combination with sofosbuvir as an all-oral, interferon- and ribavirin-free treatment option for genotype 1 chronic hepatitis C (CHC) infection in adult patients as part of a combination antiviral treatment regimen. Sofosbuvir is an HCV nucleotide analog NS5B polymerase inhibitor developed by Gilead Sciences, Inc.

Published
07 November 2014
From
Johnson & Johnson press release
Bristol-Myers Plan to Widen Access to its Hep C Drug is Criticized

“Unfortunately, history seems to be repeating itself with BMS, who hasn’t learned from the company’s poor track record responding to the HIV epidemic,” says Rohit Malpani of Doctors Without Borders.

Published
05 November 2014
From
Wall Street Journal
Half of people with hepatitis C unaware

Dr Vivian Hope of Public Health England said: "With around half of those people living with hepatitis C still unaware of their infection, we need to do more to increase diagnosis rates. Ultimately, this will help reduce the current high level of infection we’re still seeing among people who inject drugs."

Published
05 November 2014
From
Public Health England press release
Bristol-Myers Squibb announces HCV global access plans

Bristol-Myers Squibb’s HCV developing world access approach will utilize tiered pricing, licensing agreements and working in collaboration with other stakeholders who share in our commitment to working toward the eradication of hepatitis C.

Published
03 November 2014
From
Bristol-Myers Squibb press release
Opioid Maintenance Therapy Linked to Lower Hepatitis C Rates for People Who Inject Drugs

Young drug injectors who undergo opioid agonist maintenance therapy using buprenorphine or methadone have a lower likelihood of becoming infected with hepatitis C virus (HCV) than those who continue injecting or use other types of substance use treatment, according to a study published in the October 27 edition of JAMA Internal Medicine.

Published
29 October 2014
From
HIVandhepatitis.com
Australia's rejection of costly new treatment sofosbuvir a 'death sentence for for Hepatitis C sufferers'

Dr Miriam Levy, the director of gastroenterology at Sydney's Liverpool Hospital, told the conference on Thursday that the recent decision by the Pharmaceutical Benefits Advisory Committee (PBAC) to refuse subsidies for a breakthrough treatment for Hepatitis C had effectively delivered a death sentence to up to 50,000 Australians who would die from the disease in the next few years.

Published
27 October 2014
From
ABC Online
AbbVie 3D HCV regimen well-tolerated in PEARL trials

AbbVie's 3D hepatitis C regimen containing paritaprevir (ABT-450), ombitasvir, and dasabuvir was generally well-tolerated in the Phase 3 PEARL trials, according to a pooled analysis presented at IDWeek

Published
24 October 2014
By
Liz Highleyman
Ireland: Hepatitis C drug to be made available

Minister for Health Leo Varadkar is to make available potentially life-saving treatments for hepatitis C – provided agreement on price can be reached with the manufacturers.

Published
22 October 2014
From
The Irish Times

Filter by country